TY - STD TI - Hutchinson M. Natalizumab: a new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2007;3:259–68. ID - ref1 ER - TY - JOUR AU - Engelhardt, B. AU - Kappos, L. PY - 2008 DA - 2008// TI - Natalizumab: targeting alpha4-integrins in multiple sclerosis JO - Neurodegener Dis VL - 5 UR - https://doi.org/10.1159/000109933 DO - 10.1159/000109933 ID - Engelhardt2008 ER - TY - JOUR AU - Clifford, D. B. AU - DeLuca, A. AU - Simpson, D. M. AU - Arendt, G. AU - Giovannoni, G. AU - Nath, A. PY - 2010 DA - 2010// TI - Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases JO - Lancet Neurol VL - 9 UR - https://doi.org/10.1016/S1474-4422(10)70028-4 DO - 10.1016/S1474-4422(10)70028-4 ID - Clifford2010 ER - TY - JOUR AU - Bloomgren, G. AU - Richman, S. AU - Hotermans, C. AU - Subramanyam, M. AU - Goelz, S. AU - Natarajan, A. PY - 2012 DA - 2012// TI - Risk of natalizumab-associated progressive multifocal leukoencephalopathy JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1107829 DO - 10.1056/NEJMoa1107829 ID - Bloomgren2012 ER - TY - JOUR AU - Stüve, O. AU - Cravens, P. D. AU - Frohman, E. M. AU - Phillips, J. T. AU - Remington, G. M. AU - Geldern, G. PY - 2009 DA - 2009// TI - Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy JO - Neurology VL - 72 UR - https://doi.org/10.1212/01.wnl.0000327341.89587.76 DO - 10.1212/01.wnl.0000327341.89587.76 ID - Stüve2009 ER - TY - JOUR AU - Stüve, O. PY - 2008 DA - 2008// TI - The effects of natalizumab on the innate and adaptive immune system in the central nervous system JO - J Neurol Sci VL - 274 UR - https://doi.org/10.1016/j.jns.2008.03.022 DO - 10.1016/j.jns.2008.03.022 ID - Stüve2008 ER - TY - JOUR AU - Khatri, B. O. AU - Man, S. AU - Giovannoni, G. AU - Koo, A. P. AU - Lee, J. -. C. AU - Tucky, B. PY - 2009 DA - 2009// TI - Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function JO - Neurology VL - 72 UR - https://doi.org/10.1212/01.wnl.0000341766.59028.9d DO - 10.1212/01.wnl.0000341766.59028.9d ID - Khatri2009 ER - TY - STD TI - Wipfler P, Harrer A, Pilz G, Oppermann K, Afazel S, Haschke-Becher E, et al. Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal? Acta Neurol Scand. 2013:129(3):e12-5. ID - ref8 ER - TY - JOUR AU - Sheremata, W. A. AU - Vollmer, T. L. AU - Stone, L. A. AU - Willmer-Hulme, A. J. AU - Koller, M. PY - 1999 DA - 1999// TI - A safety and pharmacokinetic study of intravenous natalizumab in patients with MS JO - Neurology VL - 52 UR - https://doi.org/10.1212/WNL.52.5.1072 DO - 10.1212/WNL.52.5.1072 ID - Sheremata1999 ER - TY - STD TI - Harrer A, Pilz G, Wipfler P, Oppermann K, Sellner J, Hitzl W, et al. High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis. Clin Exp Immunol. 2015:180(3):383-92. ID - ref10 ER - TY - STD TI - Salhofer-Polanyi S, Baumgartner A, Kraus J, Maida E, Schmied M, Leutmezer F. What to expect after natalizumab cessation in a real-life setting. Acta Neurol Scand. 2014:130(2):97-102. ID - ref11 ER - TY - STD TI - Prosperini L, Annovazzi P, Capobianco M, Capra R, Buttari F, Gasperini C, et al. Natalizumab discontinuation in patients with multiple sclerosis: profiling risk and benefits at therapeutic crossroads. Mult Scler. 2015;:1352458515570768. ID - ref12 ER - TY - JOUR AU - Tanaka, M. AU - Kinoshita, M. AU - Foley, J. F. AU - Tanaka, K. AU - Kira, J. AU - Carroll, W. M. PY - 2015 DA - 2015// TI - Body weight-based natalizumab treatment in adult patients with multiple sclerosis JO - J Neurol Springer Berlin Heidelberg VL - 262 ID - Tanaka2015 ER - TY - STD TI - Gerdes LA, Meinl I, Krumbholz M, Faber H, Weber F, Pellkofer HL, et al. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol. 2011:258(9):1665-9. ID - ref14 ER - TY - JOUR AU - Ziemssen, T. AU - Kempcke, R. AU - Eulitz, M. AU - Großmann, L. AU - Suhrbier, A. AU - Thomas, K. PY - 2013 DA - 2013// TI - Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients JO - J Neural Transm VL - 120 UR - https://doi.org/10.1007/s00702-013-1041-x DO - 10.1007/s00702-013-1041-x ID - Ziemssen2013 ER - TY - JOUR AU - Shapiro, R. I. AU - Plavina, T. AU - Schlain, B. R. AU - Pepinsky, R. B. AU - Garber, E. A. AU - Jarpe, M. PY - 2011 DA - 2011// TI - Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri(®)) with endogenous IgG4 JO - J Pharm Biomed Anal VL - 55 UR - https://doi.org/10.1016/j.jpba.2011.01.006 DO - 10.1016/j.jpba.2011.01.006 ID - Shapiro2011 ER - TY - JOUR AU - Rispens, T. AU - Leeuwen, A. V. AU - Vennegoor, A. AU - Killestein, J. AU - Aalberse, R. C. AU - Wolbink, G. J. PY - 2011 DA - 2011// TI - Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody JO - Anal Biochem VL - 411 UR - https://doi.org/10.1016/j.ab.2011.01.001 DO - 10.1016/j.ab.2011.01.001 ID - Rispens2011 ER - TY - STD TI - Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Mult Scler. 2011:18(6):899-901. ID - ref18 ER - TY - JOUR AU - Benkert, T. F. AU - Dietz, L. AU - Hartmann, E. M. AU - Leich, E. AU - Rosenwald, A. AU - Serfling, E. PY - 2012 DA - 2012// TI - Natalizumab exerts direct signaling capacity and supports a Pro-inflammatory phenotype in some patients with multiple sclerosis. Dieli F, editor JO - PLoS One VL - 7 UR - https://doi.org/10.1371/journal.pone.0052208 DO - 10.1371/journal.pone.0052208 ID - Benkert2012 ER - TY - JOUR AU - Börnsen, L. AU - Christensen, J. R. AU - Ratzer, R. AU - Oturai, A. B. AU - Sørensen, P. S. AU - Søndergaard, H. B. PY - 2012 DA - 2012// TI - Effect of natalizumab on circulating CD4(+) T-cells in multiple sclerosis JO - PLoS One VL - 7 UR - https://doi.org/10.1371/journal.pone.0047578 DO - 10.1371/journal.pone.0047578 ID - Börnsen2012 ER - TY - JOUR AU - Lindberg, R. L. P. AU - Achtnichts, L. AU - Hoffmann, F. AU - Kuhle, J. AU - Kappos, L. PY - 2008 DA - 2008// TI - Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients JO - J Neuroimmunol VL - 194 UR - https://doi.org/10.1016/j.jneuroim.2007.11.007 DO - 10.1016/j.jneuroim.2007.11.007 ID - Lindberg2008 ER - TY - JOUR AU - Wilson, E. H. AU - Weninger, W. AU - Hunter, C. A. PY - 2010 DA - 2010// TI - Trafficking of immune cells in the central nervous system JO - J Clin Invest American Society for Clinical Investigation VL - 120 UR - https://doi.org/10.1172/JCI41911 DO - 10.1172/JCI41911 ID - Wilson2010 ER - TY - JOUR AU - Stüve, O. AU - Marra, C. M. AU - Bar-Or, A. AU - Niino, M. AU - Cravens, P. D. AU - Cepok, S. PY - 2006 DA - 2006// TI - Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis JO - Arch Neurol VL - 63 UR - https://doi.org/10.1001/archneur.63.10.1383 DO - 10.1001/archneur.63.10.1383 ID - Stüve2006 ER - TY - JOUR AU - Schneider-Hohendorf, T. AU - Rossaint, J. AU - Mohan, H. AU - Böning, D. AU - Breuer, J. AU - Kuhlmann, T. PY - 2014 DA - 2014// TI - VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells JO - Journal of Experimental Medicine VL - 211 UR - https://doi.org/10.1084/jem.20140540 DO - 10.1084/jem.20140540 ID - Schneider-Hohendorf2014 ER - TY - JOUR AU - Yu, Y. AU - Schürpf, T. AU - Springer, T. A. PY - 2013 DA - 2013// TI - How natalizumab binds and antagonizes α4 integrins JO - Journal of Biological Chemistry American Society for Biochemistry and Molecular Biology VL - 288 ID - Yu2013 ER - TY - JOUR AU - Sechler, J. L. AU - Cumiskey, A. M. AU - Gazzola, D. M. AU - Schwarzbauer, J. E. PY - 2000 DA - 2000// TI - A novel RGD-independent fibronectin assembly pathway initiated by alpha4beta1 integrin binding to the alternatively spliced V region JO - J Cell Sci VL - 113 ID - Sechler2000 ER - TY - JOUR AU - Hyun, Y. -. M. AU - Chung, H. -. L. AU - McGrath, J. L. AU - Waugh, R. E. AU - Kim, M. PY - 2009 DA - 2009// TI - Activated integrin VLA-4 localizes to the lamellipodia and mediates T cell migration on VCAM-1 JO - J Immunol VL - 183 UR - https://doi.org/10.4049/jimmunol.0803388 DO - 10.4049/jimmunol.0803388 ID - Hyun2009 ER - TY - JOUR AU - Rice, G. P. A. AU - Hartung, H. -. P. AU - Calabresi, P. A. PY - 2005 DA - 2005// TI - Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale JO - Neurology VL - 64 UR - https://doi.org/10.1212/01.WNL.0000158329.30470.D0 DO - 10.1212/01.WNL.0000158329.30470.D0 ID - Rice2005 ER - TY - JOUR AU - Nojima, Y. AU - Humphries, M. J. AU - Mould, A. P. AU - Komoriya, A. AU - Yamada, K. M. AU - Schlossman, S. F. PY - 1990 DA - 1990// TI - VLA-4 mediates CD3-dependent CD4+ T cell activation via the CS1 alternatively spliced domain of fibronectin JO - J Exp Med VL - 172 UR - https://doi.org/10.1084/jem.172.4.1185 DO - 10.1084/jem.172.4.1185 ID - Nojima1990 ER - TY - JOUR AU - Bomprezzi, R. AU - Pawate, S. PY - 2014 DA - 2014// TI - Extended interval dosing of natalizumab: a two-center, 7-year experience JO - Ther Adv Neurol Disord VL - 7 UR - https://doi.org/10.1177/1756285614540224 DO - 10.1177/1756285614540224 ID - Bomprezzi2014 ER - TY - STD TI - Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatr. 2016;in press: doi:10.1136/jnnp-2015-312940. ID - ref31 ER - TY - STD TI - Fox RJ, Campbell Cree BA, de Seze J, Gold R, Hartung H-P, Jeffery D, et al. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology. 2014;82(17):1491-8. doi:10.1212/WNL.0000000000000355 ID - ref32 ER - TY - JOUR AU - Svenningsson, A. AU - Sundström, P. AU - Salzer, J. AU - Vågberg, M. AU - Fox, R. J. PY - 2014 DA - 2014// TI - MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study JO - Neurology VL - 83 UR - https://doi.org/10.1212/01.wnl.0000457455.74798.9a DO - 10.1212/01.wnl.0000457455.74798.9a ID - Svenningsson2014 ER - TY - JOUR AU - Karceski, S. PY - 2014 DA - 2014// TI - The RESTORE trial: what did we learn about multiple sclerosis? JO - Neurology VL - 82 UR - https://doi.org/10.1212/WNL.0000000000000423 DO - 10.1212/WNL.0000000000000423 ID - Karceski2014 ER - TY - STD TI - Hassoun L, Eisele J, Thomas K, Ziemssen T.  Hands on Alemtuzumab-experience from clinical practice: whom and how to treat. Multiple Sclerosis and Demyelinating Disorders. 2016. in press. doi:10.1186/s40893-016-0011-1 ID - ref35 ER - TY - JOUR AU - Pilz, G. AU - Harrer, A. AU - Oppermann, K. AU - Wipfler, P. AU - Golaszewski, S. AU - Afazel, S. PY - 2012 DA - 2012// TI - Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies JO - Mult Scler VL - 18 UR - https://doi.org/10.1177/1352458511423650 DO - 10.1177/1352458511423650 ID - Pilz2012 ER - TY - STD TI - Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler. 2012:19(5):593-600. ID - ref37 ER - TY - JOUR AU - Haghikia, A. AU - Fischer, M. AU - Hellwig, K. AU - Linker, R. AU - Chan, A. AU - Hohlfeld, R. PY - 2008 DA - 2008// TI - Open use of natalizumab. Neutralising antibodies and clinical data JO - Nervenarzt VL - 79 UR - https://doi.org/10.1007/s00115-008-2464-8 DO - 10.1007/s00115-008-2464-8 ID - Haghikia2008 ER - TY - JOUR AU - Calabresi, P. A. AU - Giovannoni, G. AU - Confavreux, C. AU - Galetta, S. L. AU - Havrdova, E. AU - Hutchinson, M. PY - 2007 DA - 2007// TI - The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL JO - Neurology VL - 69 UR - https://doi.org/10.1212/01.wnl.0000277457.17420.b5 DO - 10.1212/01.wnl.0000277457.17420.b5 ID - Calabresi2007 ER - TY - JOUR AU - Serana, F. AU - Chiarini, M. AU - Sottini, A. AU - Bertoli, D. AU - Giustini, V. AU - Vaglio Tessitore, M. PY - 2014 DA - 2014// TI - Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy JO - J Neuroimmunol VL - 277 UR - https://doi.org/10.1016/j.jneuroim.2014.10.011 DO - 10.1016/j.jneuroim.2014.10.011 ID - Serana2014 ER -